Literature DB >> 18534960

Response of malignant thymoma to erlotinib.

C Christodoulou1, S Murray2, J Dahabreh3, K Petraki2, A Nikolakopoulou2, A Mavri4, D Skarlos2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18534960     DOI： 10.1093/annonc/mdn388

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  11 in total

1.  Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features.

Authors:  Hyun-Sung Lee; Hee-Jin Jang; Rohan Shah; David Yoon; Masatsugu Hamaji; Ori Wald; Ju-Seog Lee; David J Sugarbaker; Bryan M Burt
Journal:  Clin Cancer Res       Date:  2017-04-11       Impact factor: 12.531

2.  Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.

Authors:  Shirish M Gadgeel; Danika L Lew; Timothy W Synold; Patricia LoRusso; Vincent Chung; Scott D Christensen; David C Smith; Laura Kingsbury; Antje Hoering; Razelle Kurzrock
Journal:  Cancer Chemother Pharmacol       Date:  2013-09-22       Impact factor: 3.333

3.  Thymic Epithelial Tumors phenotype relies on miR-145-5p epigenetic regulation.

Authors:  Teresa Bellissimo; Federica Ganci; Enzo Gallo; Andrea Sacconi; Claudia Tito; Luciana De Angelis; Claudio Pulito; Silvia Masciarelli; Daniele Diso; Marco Anile; Vincenzo Petrozza; Felice Giangaspero; Edoardo Pescarmona; Francesco Facciolo; Federico Venuta; Mirella Marino; Giovanni Blandino; Francesco Fazi
Journal:  Mol Cancer       Date:  2017-05-10       Impact factor: 27.401

4.  An unusual case of malignant thymoma associated graft-versus-host disease.

Authors:  Faye Sara Gishen; Adrian J Tookman
Journal:  BMJ Case Rep       Date:  2009-08-19

Review 5.  Targeted therapy for advanced thymic tumors.

Authors:  Arun Rajan; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

6.  Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.

Authors:  Nicolas Girard; Ronglai Shen; Tianhua Guo; Maureen F Zakowski; Adriana Heguy; Gregory J Riely; James Huang; Christopher Lau; Alex E Lash; Marc Ladanyi; Agnes Viale; Cristina R Antonescu; William D Travis; Valerie W Rusch; Mark G Kris; William Pao
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

7.  Protein expression status of p53 and epidermal growth factor receptor in thymoma.

Authors:  Fei Cui; Jianxing He; Jun Liu; Yijiang Chen
Journal:  Oncol Lett       Date:  2011-03-14       Impact factor: 2.967

8.  Emerging treatment options for patients with recurrent advanced thymic epithelial tumors.

Authors:  Tracey L Evans
Journal:  Onco Targets Ther       Date:  2012-09-07       Impact factor: 4.147

9.  Acute respiratory distress due to thymoma in a patient treated with TK inhibitor: a case report and review of the current treatment options.

Authors:  P Zarogoulidis; D Matthaios; A Iordanidis; V Zervas; A Mitrakas; G Kouliatsis; K Zarogoulidis
Journal:  Case Rep Oncol       Date:  2011-03-22

Review 10.  [Research status of molecular targeted therapy in thymic epithelial tumors].

Authors:  Lizhu Chen; Kailiang Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.